• Carvolix priced a EUR 10 million private placement via 2,976,190 new ordinary shares at EUR 3.36 each, issued without pre-emptive rights.
• Edwards Lifesciences invested EUR 5 million; Truffle Capital funds invested EUR 5 million.
• Proceeds earmarked for product development, led by Tavipilot commercialization; EUR 2.5 million allocated to repay a Truffle Capital bridge loan.
• Cash runway expected to extend to end-September 2026; venture debt talks target about EUR 25 million to push runway beyond 12 months.
• New shares expected to settle around June 26, 2026; issuance represents about 5.02% of share capital, lifting total shares to 62,227,990.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carvolix SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2352458_en) on June 24, 2026, and is solely responsible for the information contained therein.